Clinical Trial Starts & Stops — week ending August 29, 2026
This edition covers ClinicalTrials.gov registry events from 2026-08-23 to 2026-08-29, with 997 starts, 134 stops, 951 completions, and 15 FDA approvals.
Why trials stopped
| Reason | Trials | Tone |
|---|---|---|
| Enrollment or accrual | 34 | neutral |
| No reason given | 30 | neutral |
| Funding | 19 | neutral |
| Stated, but not classifiable | 19 | neutral |
| Sponsor or business decision | 15 | neutral |
| Supply, equipment or protocol | 7 | neutral |
| Administrative or investigator | 3 | neutral |
| Regulatory or approval | 2 | neutral |
| Planned protocol transition | 2 | neutral |
| Safety | 2 | negative |
| Futility or no benefit | 1 | negative |
The most frequent reasons for stopping trials this week were related to enrollment or accrual (34 trials) and instances where no specific reason was provided (30 trials). Funding issues also accounted for a notable number of stops (19 trials).
Halts worth knowing about
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Phase 3, TERMINATED by Diamyd Medical AB on 2026-08-26 for Type 1 Diabetes Mellitus. 321 actual enrollment. "Stopped for futility." https://clinicaltrials.gov/study/NCT05018585
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase 3, TERMINATED by Bristol-Myers Squibb on 2026-08-26 for Colorectal Neoplasms. 769 actual enrollment. No reason was provided by the sponsor. https://clinicaltrials.gov/study/NCT05328908
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Phase 3, SUSPENDED by National Cancer Institute (NCI) on 2026-08-24 for Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8. 278 estimated enrollment. "End of Initial Phase of Multi-phase protocol" https://clinicaltrials.gov/study/NCT03604991
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 3, SUSPENDED by National Cancer Institute (NCI) on 2026-08-24 for High Grade Osteosarcoma, Localized Osteosarcoma. 1122 estimated enrollment. "Other - Extend the observation period for current patients" https://clinicaltrials.gov/study/NCT05691478
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Phase 3, SUSPENDED by National Cancer Institute (NCI) on 2026-08-24 for Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma. 420 estimated enrollment. "Other - Other" https://clinicaltrials.gov/study/NCT06568172
Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
Phase 4, WITHDRAWN by Cellution Biologics on 2026-08-27 for Partial Thickness Burn. 0 actual enrollment. "Change in company strategy." https://clinicaltrials.gov/study/NCT07489560
Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
Phase 4, WITHDRAWN by Cellution Biologics on 2026-08-27 for Dry Eye Disease (DED). 0 actual enrollment. "Change in company strategy." https://clinicaltrials.gov/study/NCT07529899
Age and Response to Flu Vaccines
Phase 4, TERMINATED by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-08-28 for Influenza, Influenza Immunisation. 152 actual enrollment. "Study visits could not be completed for all enrolled participants due to COVID-19 Pandemic" https://clinicaltrials.gov/study/NCT03328325
Halts by phase
| Phase | Count | Industry Sponsor |
|---|---|---|
| Phase 3 | 5 | 2 |
| Phase 2 | 43 | 4 |
| Phase 1 and 1/2 | 21 | 6 |
| Phase 4 | 4 | 2 |
| No drug phase (device, behavioural, procedural) | 39 | 5 |
| Phase not stated | 22 | 8 |
New registrations
| Phase | Count | Industry Sponsor |
|---|---|---|
| Phase 3 | 51 | 34 |
| Phase 2 | 88 | 24 |
| Phase 1 and 1/2 | 71 | 43 |
| Phase 4 | 34 | 3 |
| No drug phase (device, behavioural, procedural) | 532 | 35 |
| Phase not stated | 221 | 32 |
Completions
| Phase | Count | Industry Sponsor |
|---|---|---|
| Phase 3 | 58 | 30 |
| Phase 2 | 88 | 35 |
| Phase 1 and 1/2 | 80 | 36 |
| Phase 4 | 29 | 5 |
| No drug phase (device, behavioural, procedural) | 451 | 43 |
| Phase not stated | 245 | 15 |
FDA approvals
| Application Number | Brand Name | Sponsor | Submission Type | Submission Class | Date |
|---|---|---|---|---|---|
| NDA217806 | ZEPBOUND | ELI LILLY AND CO | SUPPL | Efficacy | 2026-08-26 |
| BLA761416 | ZIIHERA | JAZZ PHARMS | SUPPL | Efficacy | 2026-08-25 |
| BLA761232 | TEVIMBRA | BEIGENE | SUPPL | Efficacy | 2026-08-25 |
| NDA204790 | TIVICAY | VIIV HLTHCARE | SUPPL | Efficacy | 2026-08-25 |
| NDA213983 | TIVICAY PD | VIIV HLTHCARE | SUPPL | Efficacy | 2026-08-25 |
| BLA761430 | IMAAVY | JANSSEN BIOTECH | SUPPL | Efficacy | 2026-08-24 |
All 6 of the listed approvals were for efficacy supplements.
Methodology
ClinicalTrials.gov registrations and status changes, plus FDA drug approvals from openFDA. A registry status change is what the sponsor reported and when they reported it, which is not necessarily when it happened. Routine FDA labeling and manufacturing supplements are counted but not listed; only new or expanded indications are. The reason classification for trial stops is a proprietary system that analyzes the whyStopped field from ClinicalTrials.gov. Phase 1/2 trials are grouped into "Phase 1 and 1/2" and trials with no specified phase are grouped into "Phase not stated".
Rubric version: trials/v1